Olema Pharmaceuticals, Inc. OLMA Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -42.9%-1.3pp | -36.6%+2.5pp | -59.2%-7.5pp | -49.7%+6.7pp | -41.6%+6.7pp | |
| Return on assets | -39.4%-1.1pp | -33%+2.6pp | -51.5%-4.6pp | -44.7%+6.0pp | -38.3%+5.0pp | |
| Return on invested capital | -52.9%+0.1pp | -50.9%+11.1pp | -75.4%+8.2pp | -62%+9.4pp | -53%+11.3pp | |
| Liquidity | ||||||
| Current ratio | 10.9×-4.3× | 10×-0.5× | 8×+0.9× | 11.1×+2.0× | 15.2×+5.6× | |
| Quick ratio | 10.9×-4.3× | 10×-0.5× | 8×+0.9× | 11.1×+2.0× | 15.2×+5.6× | |
| Cash ratio | 1.1×-0.8× | 0.9×-2.4× | 0.8×-0.3× | 1.6×+0.9× | 1.9×+0.7× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $4.67+4.1% | $5.50-21.0% | $3.59+3.3% | $4.040.0% | $4.49+5.6% | |
| Valuation | ||||||
| Market capitalization | $973.05M+253% | $2B+366% | $671.93M0.0% | $320.9M-46.6% | $256.93M-58.6% | |
| Enterprise value | $921.46M+306% | $1.96B+570% | $638.15M+0.1% | $270.18M-53.9% | $207.44M-64.8% | |
| Price / book | 2.1×+1.3× | 4.2×+3.1× | 2.2×-1.2× | 0.9×-1.7× | 0.7×-2.0× | |
| Earnings yield | -18.5%+27.1pp | -8.1%+22.0pp | -22.3%-4.1pp | -44.3%-26.1pp | -50.2%-34.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Olema Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from Olema Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.